RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)

RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)

Key details

What this opportunity is and why it matters

RFA-HL-26-003 is an NIH notice of funding opportunity for the NHLBI Emerging Investigator Award (EIA). It is an R35-style mechanism aimed at investigators who already have a substantial NHLBI research track record. Unlike project grants tied to a narrow set of predefined aims, this award is designed to support a research program more broadly and for a longer horizon, allowing a PI to move more fluidly between hypotheses and directions that emerge during the research arc.

The page frames the award as a flexibility mechanism for people who are already productive but constrained by the normal rhythm of short-cycle grant writing and portfolio maintenance. The NOFO says the intent is to reduce the burden of writing multiple competing applications while improving continuity of support in HLBS (heart, lung, blood, and sleep) areas. The award is therefore attractive for established investigators who do not need a starter program to begin a career, but who need room to pursue high-risk/high-reward lines of work, shift methods when opportunity appears, and maintain momentum.

For applicants, the practical distinction is this: a standard project grant usually requires a tightly defined set of aims and deliverables for the period. The EIA instead emphasizes a program perspective and institutional commitment to keep one investigator’s work coherent over time. In exchange, NHLBI expects serious strategic focus, strong prior competitiveness, and alignment with mission-relevant science.

What exactly the EIA can and cannot support

The NOFO says the award is not a supplemental top-up to unrelated workstreams. It is intended to be the primary source of NHLBI funding for the recipient’s NHLBI research and is typically the most likely sole support for that person’s NHLBI-related program funding at that time.

The award is explicitly for research within NHLBI scope. The NOFO permits a broad interpretation of scientific direction within HLBS but flags that work outside mission boundaries is not responsive and can fail review at the administrative gate.

The offer is not unlimited and not automatically renewable beyond the stated period. It is for up to seven years, with funding level set at the end of review and program deliberation. The NOFO text does not publish a fixed dollar ceiling or guaranteed award amount. That means if you are advising an applicant, treat this as a strategic fit and long-horizon fit, not a guaranteed budget-targeted opportunity.

The NOFO also notes what is not allowed in this mechanism: non-mechanistic Phase I/II/III/T4 clinical trials are excluded from being responsive, and the application must include clear positioning that complies with the review and compliance expectations.

Who is eligible

Eligibility has hard constraints, and this is where teams often lose time if they only do a surface read. NIH spells out that the PI must be currently PI on at least two NHLBI R01-equivalent awards (R01, DP1, DP2). At least one of those must be a single-PD/PI NHLBI-funded ESI R01. That qualifying award must not be in no-cost extension and must satisfy additional NIH trial constraints unless the trial is mechanistic/BESH type in permitted form.

The additional qualifying award can be multiple-PD/PI or in a first no-cost extension, but the minimum bar of two qualifying awards remains strict. In practical terms, this means the applicant is usually already mid-to-late in an NIH-funded trajectory with demonstrated NHLBI relevance, not a new PI.

Another hard filter is single-PD/PI only: applications with multiple PIs are explicitly ineligible. The PI must also commit at least 6 person months throughout the EIA duration, which the NIH interprets as 50% effort for a full-time (12-month) appointment, ~66.67% for 9-month appointment, or full-time on a 6-month appointment.

The NOFO does not require cost sharing, which is good for planning, but it does require a Letter of Support from the Authorized Organization Representative. For many applicants this is administratively simple but strategically important: the letter must confirm effort commitment, identify the two qualifying NHLBI awards, document institutional commitment, and accept award conditions including award replacement behavior. If this letter is missing, the application is treated as not responsive and is not reviewed.

Geography, funding model, and applicant profile fit

Because this is an NIH/NHLBI mechanism administered through U.S. federal systems, you should treat it as an opportunity for organizations that can submit through ASSIST, Grants.gov Workspace, or an institutional S2S pathway and that can provide an eRA Commons account structure compliant with NIH rules. The mechanism is best for:

• Established NHLBI investigators with a proven independent funding base.
• Labs already running multi-year, mission-aligned HLBS programs where flexibility in direction would materially improve productivity.
• Candidates with enough organizational support to absorb the transition from multiple R01-style projects into one coherent EIA-supported program.

It is less appropriate for new investigators, teams trying to bypass R01-style collaboration norms, and institutions that cannot document protected research effort or compliant systems.

Key timeline and what “currently open” means for 2026/2027 planning

The opportunity page states posted and key date points with multiple cycles, including February 19 due dates in 2025, 2026, and 2027. The posted data indicates the current opportunity has an expiration date of April 29, 2027. Even when one cycle has passed, later-cycle windows can continue to be relevant for teams with institutional clearance and compliant applications.

For this task’s timeline, the practical planning date to anchor is:

• Next listed application due date: 2027-02-19
• review and start date windows (as listed in the NOFO): review in April, council review in July, earliest start in October, with award action in December for active cycles

This is useful because teams often ask whether a date has passed only once and then stop. The right planning method is to treat each NOFO cycle separately and confirm the exact “application due date” column and any NIH policy updates released after the posting.

When building your internal plan, map backward from the cycle due date:

• minus 12 to 14 weeks: draft specific aims and investigator statement
• minus 10 to 12 weeks: finalize LOI and collect institutional letters
• minus 6 to 8 weeks: complete forms, budget narrative, and DMSP
• minus 2 to 4 weeks: internal mock review and portal/system validation

The NIH explicitly asks early submission to allow correction windows, which matters because technical errors in NIH systems can block acceptance even for strong science.

Application materials and compliance requirements

The technical stack is standard NIH submission logic but strict: ASSIST, Grants.gov Workspace, or institutional S2S with eRA Commons linkage. All PD/PI(s) need valid eRA Commons accounts, and institutional admin must be fully configured before submission.

For this NOFO specifically, non-negotiables include:

• No-cost sharing requirement (explicitly none)
• Letter of Support from AOR, max 2 pages
• LOA must state PI effort commitment, eligibility evidence, institution support, and acceptance of replacing most existing NHLBI research awards while accepting EIA
• Strict adherence to page limits and NIH Application Guide
• Data Management and Sharing Plan (now in the Other Plan(s) section), regardless of requested direct cost size
• Limited appendix policy; no publications unless allowed blanks (no CV packs or evidence dump)

The NOFO also references existing scientific review and human subjects instructions, which means teams need to keep inclusion and ethical sections compliant if relevant. This is especially important for HLBS teams with translational components, because noncompliance can cause technical return before peer review.

A practical operational warning: if any instruction says “not responsive,” it is not merely a scoring issue. It can become a hard filter. The NIH reviewers and systems both enforce these gates.

How applications are reviewed and what NIH reviewers prioritize

The EIA is reviewable through the regular NIH framework for these programs. While the details in the NOFO include scoring rubrics by category, the most useful applicant takeaway is this: the review is not just about a single aim sequence. It evaluates the research program trajectory, expected impact, rigor, investigator readiness, and the reasoned use of the flexibility this mechanism offers.

The application must clearly show:

• why a seven-year stable funding model changes what the PI can do now
• how the PI will manage flexibility while still producing progress
• continuity strategy across methods, hypotheses, and translational bridges
• a compelling case for fit within NHLBI mission

Mechanistic clinical studies can be addressed if properly framed; non-mechanistic large efficacy trials do not belong in this mechanism and should be excluded from this NOFO submission strategy.

The LOA, the research environment narrative, and the transition plan from prior NHLBI grants are often decisive evidence points. If you can explain the intended evolution from prior funded work and show institutional safeguards around protected time, this tends to reassure reviewers that the award will produce durable output, not just a single short burst of projects.

Strategy checklist for a strong EIA submission

1) Confirm hard eligibility before drafting

Use a checklist with your office: current award list, single-PD/PI requirement, non-NCE condition, and NHLBI ESI R01 presence. Do this before writing abstract text. If it fails here, no amount of scientific narrative rescues the submission.

2) Align institutional commitments early

Institutional support can make or break an application. Because NIH requires LOA with explicit commitments and commitment to the PI’s 6 person months, get these documents aligned in parallel with science sections. Don’t wait until week -4.

3) Build the program narrative around risk and adaptability

This award rewards long-horizon thinking. Your narrative should explicitly describe which lines are high-confidence versus exploratory, and how the PI will pivot responsibly while staying within HLBS scope.

4) Keep appendix clean

Use only permitted materials. A frequent mistake in large institutions is stuffing appendices with legacy publications or extra letters that conflict with page limits. The NOFO is explicit on this point.

5) Use NIH portals without urgency risk

Register in eRA Commons and Grants.gov well ahead of deadline; NIH’s note about submission windows indicates they treat correction windows as normal, but only if applicants submit early enough to catch rejections.

6) Prepare review-facing narrative for two audiences

Reviewers and program officers have different reading goals. Reviewers need compelling significance and feasibility. Program officers look for mission alignment and compliance with NOFO mechanics. Draft both lenses in parallel.

Common mistakes that reduce competitiveness or cause rejection

1. Submitting as multi-PD/PI when the NOFO requires single PD/PI.
2. Using a non-qualifying prior award set for the eligibility rule.
3. Treating this as a normal R01 and over-focusing on narrow experiments instead of program arc.
4. Missing the AOR Letter of Support or omitting required LOA content.
5. Ignoring data sharing plan requirements.
6. Submitting late to avoid portal glitches and then discovering an unresolved technical warning.
7. Assuming unlimited funding certainty and omitting budget rationale consistent with mission priorities.
8. Proposing disallowed non-mechanistic clinical trial content.

FAQ

Is this a new award for first-time grant applicants?

No. This is explicitly for currently funded, established investigators meeting specific NHLBI R01-equivalent criteria.

Is there a fixed grant size or salary cap?

No fixed dollar amount is published in this announcement. The NOFO says funding levels are determined by NHLBI from peer review and program factors.

Can clinical work be included?

Yes, within limits. Mechanistic and certain permitted categories can fit, but non-mechanistic Phase I/II/III/T4 trials are not allowed under this NOFO.

Can an applicant submit an R01 at the same time?

Yes, NIH notes parallel submission may be possible. If both are funded, the PI may accept either the EIA or the R01, not both for NHLBI research awards.

What is the key practical action for someone targeting the next window?

Treat February 19, 2027 as the next listed hard submission date, with systems/test cycles earlier, and include institutional LOA early.

Official links and what to verify before writing

Use these official pages directly (not aggregator mirrors) for final details:

• Official NOFO page: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-003.html
• How to Apply guide: https://grants.nih.gov/grants/how-to-apply-for-grants
• NIH policy notices and notices dashboard for updates: https://grants.nih.gov/grants/guide/notice-files/
• NHLBI funding opportunities and contacts: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts
• NIH Grants Policy Statement: https://grants.nih.gov/grants/policy

If you are building a team around this now, lock two dates immediately: the next NIH announcement updates and your institutional pre-submission compliance date. The technical stack and eligibility filters are strict by design; your best chance is to eliminate avoidable ineligibility and administrative failure early, then write a high-risk/high-reward scientific narrative that still reads like an execution plan.